1404456-53-6 Usage
Description
GSK 2830371 is a small molecule inhibitor that targets the allosteric regulation of Wip1 (wild-type p54-induced phosphatase) through flap-subdomain interaction. It plays a significant role in biological studies and has potential implications in the development of therapeutic strategies for various diseases.
Uses
Used in Biological Studies:
GSK 2830371 is used as an allosteric Wip1 inhibitor for the purpose of studying its effects on the regulation of Wip1 through flap-subdomain interaction. This application aids in understanding the role of Wip1 in cellular processes and its potential as a therapeutic target.
Used in Pharmaceutical Research:
GSK 2830371 is used as a research tool in the development of novel therapeutic strategies targeting Wip1. By inhibiting Wip1, it may help in the discovery of new drugs that can modulate the activity of this phosphatase, potentially leading to treatments for diseases where Wip1 plays a crucial role.
Used in Cancer Research:
In the field of cancer research, GSK 2830371 is used as a potential therapeutic agent for the inhibition of Wip1, which is often overexpressed in various types of cancer. By targeting Wip1, GSK 2830371 may help in the development of new treatments that can suppress tumor growth and improve the effectiveness of existing cancer therapies.
Used in Drug Delivery Systems:
Although not explicitly mentioned in the provided materials, GSK 2830371 could potentially be used in drug delivery systems to improve its bioavailability, delivery, and therapeutic outcomes. This application would involve the development of novel drug delivery platforms, such as nanoparticles or other carriers, to enhance the efficacy of GSK 2830371 in targeting Wip1 and treating related diseases.
Biochem/physiol Actions
GSK2830371 is an orally active allosteric inhibitor of wild-type p53-induced phosphatase (Wip1, also known as PPM1D/ PP2Cδ), an oncogenic type 2C serine/threonine phosphatase that negatively regulates key proteins in the DNA damage–response pathway. GSK2830371 is selective for Wip1 with an IC50 of 6 nM against Wip1 compared to >10 μM IC50 for PPM1A & PPM1K, and >30 μM IC50 for 22 other phosphatases tested. GSK2830371 is believed to interact with the flap subdomain located near the Wip1 catalytic site, a feature that distinguishes Wip1 from other members of the protein phosphatase 2C (PP2C) family. GSK2830371 increased phosphorylation of Wip1 substrates and caused growth inhibition in both hematopoietic tumor cell lines and Wip1-amplified breast tumor cells harboring wild-type TP53.
Check Digit Verification of cas no
The CAS Registry Mumber 1404456-53-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,4,4,5 and 6 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1404456-53:
(9*1)+(8*4)+(7*0)+(6*4)+(5*4)+(4*5)+(3*6)+(2*5)+(1*3)=136
136 % 10 = 6
So 1404456-53-6 is a valid CAS Registry Number.
1404456-53-6Relevant articles and documents
NOVEL COMPOUNDS AS WIP1 INHIBITORS
-
, (2012/11/13)
This invention relates to the use of acylated alanine derivatives for the modulation, notably the inhibition of the activity of WIP1. Suitably, the present invention relates to the use of acylated alanine derivatives in the treatment of cancer.
